Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.

Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA.

Inflamm Bowel Dis. 2017 Jul;23(7):1210-1217. doi: 10.1097/MIB.0000000000001117.

PMID:
28445244
2.

Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.

Edlund H, Steenholdt C, Ainsworth MA, Goebgen E, Brynskov J, Thomsen OØ, Huisinga W, Kloft C.

AAPS J. 2017 Jan;19(1):223-233. doi: 10.1208/s12248-016-9989-8. Epub 2016 Oct 13.

PMID:
27739011
3.

Monitoring immunogenicity of protein-based TNF antagonists.

Bendtzen K, Steenholdt C, Brynskov J, Thomsen OØ, Ainsworth MA.

Frontline Gastroenterol. 2016 Apr;7(2):152-154. doi: 10.1136/flgastro-2015-100596. Epub 2015 May 14. No abstract available.

4.

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.

Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM.

Vaccine. 2015 Oct 5;33(41):5464-5469. doi: 10.1016/j.vaccine.2015.08.011. Epub 2015 Aug 12.

PMID:
26275480
5.

Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.

J Crohns Colitis. 2015 Nov;9(11):1032-42. doi: 10.1093/ecco-jcc/jjv139. Epub 2015 Aug 5.

PMID:
26245216
6.

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.

Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OØ, Brynskov J.

J Clin Gastroenterol. 2016 Jul;50(6):483-9. doi: 10.1097/MCG.0000000000000375.

PMID:
26166141
7.

Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.

Christensen KR, Steenholdt C, Buhl SS, Ainsworth MA, Thomsen OØ, Brynskov J.

Am J Gastroenterol. 2015 Nov;110(11):1526-32. doi: 10.1038/ajg.2015.162. Epub 2015 Jun 2.

PMID:
26032156
8.

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12.

PMID:
25673037
9.

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.

J Crohns Colitis. 2015 Mar;9(3):238-45. doi: 10.1093/ecco-jcc/jjv004. Epub 2015 Jan 9.

PMID:
25576753
10.

Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease.

Aalykke C, Jensen MD, Fallingborg J, Jess T, Langholz E, Meisner S, Andersen NN, Riis LB, Thomsen OØ, Tøttrup A.

Dan Med J. 2015 Jan;62(1):B4995.

PMID:
25557336
11.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.

Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA.

BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887.

12.

The effects of experimentally induced adelphophagy in gastropod embryos.

Thomsen O, Collin R, Carrillo-Baltodano A.

PLoS One. 2014 Jul 29;9(7):e103366. doi: 10.1371/journal.pone.0103366. eCollection 2014.

13.

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.

Inflamm Bowel Dis. 2014 Oct;20(10):1714-21. doi: 10.1097/MIB.0000000000000138.

PMID:
25069030
14.

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Am J Gastroenterol. 2014 Jul;109(7):1055-64. doi: 10.1038/ajg.2014.106. Epub 2014 May 6.

PMID:
24796769
15.

Electrostatic discharges and their effect on the validity of registered values in intracranial pressure monitors.

Andresen M, Juhler M, Thomsen OC.

J Neurosurg. 2013 Nov;119(5):1119-24. doi: 10.3171/2013.7.JNS13506. Epub 2013 Aug 23.

PMID:
23971955
16.

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.

PMID:
23878167
17.

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.

Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K.

Ther Drug Monit. 2013 Aug;35(4):530-8. doi: 10.1097/FTD.0b013e31828d23c3.

PMID:
23765033
18.

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.

Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OØ, Bendtzen K.

Aliment Pharmacol Ther. 2012 Oct;36(7):650-9. doi: 10.1111/apt.12010. Epub 2012 Aug 5.

19.

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.

Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA.

Inflamm Bowel Dis. 2012 Dec;18(12):2209-17. doi: 10.1002/ibd.22910. Epub 2012 Feb 16.

PMID:
22344964
20.

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.

Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA.

J Crohns Colitis. 2012 Feb;6(1):108-11. doi: 10.1016/j.crohns.2011.08.001. Epub 2011 Aug 31.

PMID:
22261535
21.

World Gastroenterology Organisation global guideline: Constipation--a global perspective.

Lindberg G, Hamid SS, Malfertheiner P, Thomsen OO, Fernandez LB, Garisch J, Thomson A, Goh KL, Tandon R, Fedail S, Wong BC, Khan AG, Krabshuis JH, LeMair A; World Gastroenterology Organisation.

J Clin Gastroenterol. 2011 Jul;45(6):483-7. doi: 10.1097/MCG.0b013e31820fb914. No abstract available. Erratum in: J Clin Gastroenterol. 2011 Oct;45(9):838. J Clin Gastroenterol. 2012 Jan;46(1):90. multiple author names added.

PMID:
21666546
22.

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.

Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA.

Aliment Pharmacol Ther. 2011 Jul;34(1):51-8. doi: 10.1111/j.1365-2036.2011.04682.x. Epub 2011 May 3.

23.

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Scand J Gastroenterol. 2011 Mar;46(3):310-8. doi: 10.3109/00365521.2010.536254. Epub 2010 Nov 18.

PMID:
21087119
24.

Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.

Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ.

Aliment Pharmacol Ther. 2011 Jan;33(2):185-93. doi: 10.1111/j.1365-2036.2010.04509.x. Epub 2010 Nov 17.

25.

Comment on 'Predicting the response to infliximab from trough serum levels'.

Bendtzen K, Steenholdt C, Ainsworth M, Thomsen OØ, Brynskov J.

Gut. 2010 Sep;59(9):1298-9; author reply 1299-300. doi: 10.1136/gut.2009.206805. No abstract available.

PMID:
20801776
26.

Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.

Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators.

Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1.

PMID:
20117244
27.

[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].

Steenholdt C, Ainsworth M, Thomsen OØ, Brynskov J, Bendtzen K.

Ugeskr Laeger. 2010 Jan 4;172(1):44-7. Danish.

PMID:
20056095
28.

World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.

Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, LeMair AW, Malfertheiner, Ouyang Q, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, Watermeyer G.

Inflamm Bowel Dis. 2010 Jan;16(1):112-24. doi: 10.1002/ibd.21048.

PMID:
19653289
29.

A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations.

Borg S, Persson U, Jess T, Thomsen OØ, Ljung T, Riis L, Munkholm P.

Med Decis Making. 2010 Jan-Feb;30(1):132-42. doi: 10.1177/0272989X09336141. Epub 2009 Jul 15.

PMID:
19605883
30.

Diagnosis and management of fistulizing Crohn's disease.

Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ.

Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):92-106. doi: 10.1038/ncpgasthep1340. Epub 2009 Jan 20. Review.

PMID:
19153563
31.

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.

Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OØ, Brynskov J.

Scand J Gastroenterol. 2009;44(7):774-81. doi: 10.1080/00365520802699278. Review.

PMID:
19140087
32.

Maintenance therapy with certolizumab pegol for Crohn's disease.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators.

N Engl J Med. 2007 Jul 19;357(3):239-50. Erratum in: N Engl J Med. 2007 Sep 27;357(13):1357.

33.

Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.

Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R.

Scand J Gastroenterol. 2007 Feb;42(2):221-7.

PMID:
17327942
34.

Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OØ, Munkholm P.

Inflamm Bowel Dis. 2007 Apr;13(4):481-9.

PMID:
17206705
35.

[5-aminosalicylic acid and cancer prophylaxis?].

Thomsen OO.

Ugeskr Laeger. 2006 May 22;168(21):2047. Danish. No abstract available.

PMID:
16768920
36.

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.

Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A; CDP870 Crohn's Disease Study Group.

Gastroenterology. 2005 Sep;129(3):807-18. Erratum in: Gastroenterology. 2005 Nov;129(5):1808. Dosage error in article text.

PMID:
16143120
37.

[Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review].

Thomsen OØ, Nielsen OH.

Ugeskr Laeger. 2005 Aug 15;167(33):3015-7. Danish. No abstract available.

PMID:
16109240
38.

[Mesalamine in the treatment of Crohn disease?].

Nielsen OH, Thomsen OO.

Ugeskr Laeger. 2005 Apr 11;167(15):1656-7. Danish. No abstract available.

PMID:
15892345
39.

Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.

Usher PA, Thomsen OF, Iversen P, Johnsen M, Brünner N, Høyer-Hansen G, Andreasen P, Danø K, Nielsen BS.

Int J Cancer. 2005 Mar 1;113(6):870-80.

40.

Inflammatory bowel disease (ulcerative colitis and Crohn's disease): diagnostic criteria and differential diagnosis.

Winther KV, Føgh P, Thomsen OØ, Brynskov J.

Drugs Today (Barc). 1998 Nov;34(11):935-42.

PMID:
14743262
41.

Corticosteroids for maintenance of remission in Crohn's disease.

Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO.

Cochrane Database Syst Rev. 2003;(4):CD000301. Review.

PMID:
14583917
42.

Thiopurine methyltransferase genotype distribution in patients with Crohn's disease.

Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schmiegelow K.

Aliment Pharmacol Ther. 2003 Jan;17(1):65-8.

43.

Pyelonephritis and interstitial nephritis--clinical-pathological correlations.

Thomsen OF, Ladefoged J.

Clin Nephrol. 2002 Oct;58(4):275-81. Erratum in: Clin Nephrol. 2003 Jan;59(1):70..

PMID:
12400842
44.

Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.

Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E; International Budesonide-Mesalazine Study Group.

Am J Gastroenterol. 2002 Mar;97(3):649-53.

PMID:
11922560
45.

Corticosteroids for maintaining remission of Crohn's disease.

Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO.

Cochrane Database Syst Rev. 2001;(3):CD000301. Review. Update in: Cochrane Database Syst Rev. 2003;(4):CD000301.

PMID:
11686956
46.

Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls.

Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, Høiby N, Harms BA, Thomsen OO, Skibsted U, Binder V.

J Clin Microbiol. 2000 Dec;38(12):4373-81.

47.

Quality of life study in a regional group of patients with Crohn disease. A structured interview study.

Guassora AD, Kruuse C, Thomsen OO, Binder V.

Scand J Gastroenterol. 2000 Oct;35(10):1068-74.

PMID:
11099060
48.

Corticosteroids for maintaining remission of Crohn's disease.

Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO.

Cochrane Database Syst Rev. 2000;(2):CD000301. Review. Update in: Cochrane Database Syst Rev. 2001;(3):CD000301.

PMID:
10796525
49.

[National surveillance of Helicobacter pylori eradication in Denmark. Results based on registration of 34.582 drug prescriptions].

Juul KV, Thomsen OO, Nissen A, Hallas J, Kolmos HJ, Funch-Jensen PM, Lauritsen K.

Ugeskr Laeger. 1999 Nov 29;161(48):6635-8. Danish.

PMID:
10643349
50.

[Informed consent in connection with autopsy and sending out discharge notes. A questionnaire study].

Jensen RB, Thomsen OO.

Ugeskr Laeger. 1999 Oct 4;161(40):5531-6. Review. Danish.

PMID:
10553363

Supplemental Content

Loading ...
Support Center